Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells
To investigate the factors influencing the efficacy of CD19 chimeric antigen receptor T (CAR-T) cells in the treatment of patients with relapsed refractory B cell lymphoma and to provide evidence for further improvement of CAR-T efficacy. A total of 34 patients with relapsed and refractory B-cell ly...
Gespeichert in:
| Veröffentlicht in: | Zhong hua yi xue za zhi 2020-03, Vol.100 (8), p.593-598 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 598 |
|---|---|
| container_issue | 8 |
| container_start_page | 593 |
| container_title | Zhong hua yi xue za zhi |
| container_volume | 100 |
| creator | Xiao, X Yuan, T Meng, J X Jiang, Y Y Cao, Y Q Li, Q Sun, R Zhao, M F |
| description | To investigate the factors influencing the efficacy of CD19 chimeric antigen receptor T (CAR-T) cells in the treatment of patients with relapsed refractory B cell lymphoma and to provide evidence for further improvement of CAR-T efficacy.
A total of 34 patients with relapsed and refractory B-cell lymphoma were recruited from the Department of Hematology of Tianjin First Central Hospital from February 2017 to January 2019. All patients received CD19 CAR-T cell therapy. These patients were evaluated for efficacy, factors with poor efficacyand adverse effects.
The overall response rate was 58.8% (20/34) and the complete remission rate was 41.2% (14/34) after infusion of CD19 CAR-T cells in 34 patients with relapsed refractory B cell lymphoma. According to the efficacy of CAR-T cells, patients were divided into two groups, 20 in the effective group and 14 in the poorly effective group. The median am ount of CD19 CAR-T cell infusions in these two groups were 8.6 (5.0-12.7)×10(6)/kg and 9.7 (5.8-15.0) × 10(6)/kg, r |
| doi_str_mv | 10.3760/cma.j.issn.0376-2491.2020.08.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2377346804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2377346804</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-9f42ca8e02ab105a52822aed5199ab5d119560e794eaef9386c90ef087d2267b3</originalsourceid><addsrcrecordid>eNo9kMtqwzAQRbVoaUKaXyhaZmNHD1u2lqn7hEChpGsjyyOiYluupFD893X6Wg333MMwDEIbSlJeCLLVvUrfUxvCkJIZJCyTNGWEkZSUKSHiAi3_-QKtQ7ANyQouZ4VeoQVnVGSU8iUad4PqpmADdgMenfMYjLFa6QkbpaPzAdsBxyPg6EHFHoaIncEe9Mn7OWw9GP8tTvg20dB1uJv68eh6hT9tPOLqjkpc7V6TAz634RpdGtUFWP_OFXp7uD9UT8n-5fG52u2TkTIRE2kyplUJhKmGklzlrGRMQZtTKVWTt5TKXBAoZAYKjOSl0JKAIWXRMiaKhq_Q5mfv6N3HCUKsexvOF6gB3CnUjBcFz0RJslm9-VVPTQ9tPXrbKz_Vf1_iX8OrbNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2377346804</pqid></control><display><type>article</type><title>Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Xiao, X ; Yuan, T ; Meng, J X ; Jiang, Y Y ; Cao, Y Q ; Li, Q ; Sun, R ; Zhao, M F</creator><creatorcontrib>Xiao, X ; Yuan, T ; Meng, J X ; Jiang, Y Y ; Cao, Y Q ; Li, Q ; Sun, R ; Zhao, M F</creatorcontrib><description>To investigate the factors influencing the efficacy of CD19 chimeric antigen receptor T (CAR-T) cells in the treatment of patients with relapsed refractory B cell lymphoma and to provide evidence for further improvement of CAR-T efficacy.
A total of 34 patients with relapsed and refractory B-cell lymphoma were recruited from the Department of Hematology of Tianjin First Central Hospital from February 2017 to January 2019. All patients received CD19 CAR-T cell therapy. These patients were evaluated for efficacy, factors with poor efficacyand adverse effects.
The overall response rate was 58.8% (20/34) and the complete remission rate was 41.2% (14/34) after infusion of CD19 CAR-T cells in 34 patients with relapsed refractory B cell lymphoma. According to the efficacy of CAR-T cells, patients were divided into two groups, 20 in the effective group and 14 in the poorly effective group. The median am ount of CD19 CAR-T cell infusions in these two groups were 8.6 (5.0-12.7)×10(6)/kg and 9.7 (5.8-15.0) × 10(6)/kg, r</description><identifier>ISSN: 0376-2491</identifier><identifier>DOI: 10.3760/cma.j.issn.0376-2491.2020.08.006</identifier><identifier>PMID: 32164113</identifier><language>chi</language><publisher>China</publisher><subject>Antigens, CD19 ; Humans ; Immunotherapy, Adoptive ; Lymphoma, B-Cell ; Neoplasm Recurrence, Local ; T-Lymphocytes</subject><ispartof>Zhong hua yi xue za zhi, 2020-03, Vol.100 (8), p.593-598</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32164113$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xiao, X</creatorcontrib><creatorcontrib>Yuan, T</creatorcontrib><creatorcontrib>Meng, J X</creatorcontrib><creatorcontrib>Jiang, Y Y</creatorcontrib><creatorcontrib>Cao, Y Q</creatorcontrib><creatorcontrib>Li, Q</creatorcontrib><creatorcontrib>Sun, R</creatorcontrib><creatorcontrib>Zhao, M F</creatorcontrib><title>Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells</title><title>Zhong hua yi xue za zhi</title><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><description>To investigate the factors influencing the efficacy of CD19 chimeric antigen receptor T (CAR-T) cells in the treatment of patients with relapsed refractory B cell lymphoma and to provide evidence for further improvement of CAR-T efficacy.
A total of 34 patients with relapsed and refractory B-cell lymphoma were recruited from the Department of Hematology of Tianjin First Central Hospital from February 2017 to January 2019. All patients received CD19 CAR-T cell therapy. These patients were evaluated for efficacy, factors with poor efficacyand adverse effects.
The overall response rate was 58.8% (20/34) and the complete remission rate was 41.2% (14/34) after infusion of CD19 CAR-T cells in 34 patients with relapsed refractory B cell lymphoma. According to the efficacy of CAR-T cells, patients were divided into two groups, 20 in the effective group and 14 in the poorly effective group. The median am ount of CD19 CAR-T cell infusions in these two groups were 8.6 (5.0-12.7)×10(6)/kg and 9.7 (5.8-15.0) × 10(6)/kg, r</description><subject>Antigens, CD19</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive</subject><subject>Lymphoma, B-Cell</subject><subject>Neoplasm Recurrence, Local</subject><subject>T-Lymphocytes</subject><issn>0376-2491</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtqwzAQRbVoaUKaXyhaZmNHD1u2lqn7hEChpGsjyyOiYluupFD893X6Wg333MMwDEIbSlJeCLLVvUrfUxvCkJIZJCyTNGWEkZSUKSHiAi3_-QKtQ7ANyQouZ4VeoQVnVGSU8iUad4PqpmADdgMenfMYjLFa6QkbpaPzAdsBxyPg6EHFHoaIncEe9Mn7OWw9GP8tTvg20dB1uJv68eh6hT9tPOLqjkpc7V6TAz634RpdGtUFWP_OFXp7uD9UT8n-5fG52u2TkTIRE2kyplUJhKmGklzlrGRMQZtTKVWTt5TKXBAoZAYKjOSl0JKAIWXRMiaKhq_Q5mfv6N3HCUKsexvOF6gB3CnUjBcFz0RJslm9-VVPTQ9tPXrbKz_Vf1_iX8OrbNQ</recordid><startdate>20200303</startdate><enddate>20200303</enddate><creator>Xiao, X</creator><creator>Yuan, T</creator><creator>Meng, J X</creator><creator>Jiang, Y Y</creator><creator>Cao, Y Q</creator><creator>Li, Q</creator><creator>Sun, R</creator><creator>Zhao, M F</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20200303</creationdate><title>Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells</title><author>Xiao, X ; Yuan, T ; Meng, J X ; Jiang, Y Y ; Cao, Y Q ; Li, Q ; Sun, R ; Zhao, M F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-9f42ca8e02ab105a52822aed5199ab5d119560e794eaef9386c90ef087d2267b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2020</creationdate><topic>Antigens, CD19</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive</topic><topic>Lymphoma, B-Cell</topic><topic>Neoplasm Recurrence, Local</topic><topic>T-Lymphocytes</topic><toplevel>online_resources</toplevel><creatorcontrib>Xiao, X</creatorcontrib><creatorcontrib>Yuan, T</creatorcontrib><creatorcontrib>Meng, J X</creatorcontrib><creatorcontrib>Jiang, Y Y</creatorcontrib><creatorcontrib>Cao, Y Q</creatorcontrib><creatorcontrib>Li, Q</creatorcontrib><creatorcontrib>Sun, R</creatorcontrib><creatorcontrib>Zhao, M F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhong hua yi xue za zhi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiao, X</au><au>Yuan, T</au><au>Meng, J X</au><au>Jiang, Y Y</au><au>Cao, Y Q</au><au>Li, Q</au><au>Sun, R</au><au>Zhao, M F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells</atitle><jtitle>Zhong hua yi xue za zhi</jtitle><addtitle>Zhonghua Yi Xue Za Zhi</addtitle><date>2020-03-03</date><risdate>2020</risdate><volume>100</volume><issue>8</issue><spage>593</spage><epage>598</epage><pages>593-598</pages><issn>0376-2491</issn><abstract>To investigate the factors influencing the efficacy of CD19 chimeric antigen receptor T (CAR-T) cells in the treatment of patients with relapsed refractory B cell lymphoma and to provide evidence for further improvement of CAR-T efficacy.
A total of 34 patients with relapsed and refractory B-cell lymphoma were recruited from the Department of Hematology of Tianjin First Central Hospital from February 2017 to January 2019. All patients received CD19 CAR-T cell therapy. These patients were evaluated for efficacy, factors with poor efficacyand adverse effects.
The overall response rate was 58.8% (20/34) and the complete remission rate was 41.2% (14/34) after infusion of CD19 CAR-T cells in 34 patients with relapsed refractory B cell lymphoma. According to the efficacy of CAR-T cells, patients were divided into two groups, 20 in the effective group and 14 in the poorly effective group. The median am ount of CD19 CAR-T cell infusions in these two groups were 8.6 (5.0-12.7)×10(6)/kg and 9.7 (5.8-15.0) × 10(6)/kg, r</abstract><cop>China</cop><pmid>32164113</pmid><doi>10.3760/cma.j.issn.0376-2491.2020.08.006</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-2491 |
| ispartof | Zhong hua yi xue za zhi, 2020-03, Vol.100 (8), p.593-598 |
| issn | 0376-2491 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_2377346804 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antigens, CD19 Humans Immunotherapy, Adoptive Lymphoma, B-Cell Neoplasm Recurrence, Local T-Lymphocytes |
| title | Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T01%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20on%20poor%20efficacy%20factors%20in%20the%20treatment%20of%20recurrent/refractory%20B-cell%20lymphoma%20with%20CD19%20CAR-T%20cells&rft.jtitle=Zhong%20hua%20yi%20xue%20za%20zhi&rft.au=Xiao,%20X&rft.date=2020-03-03&rft.volume=100&rft.issue=8&rft.spage=593&rft.epage=598&rft.pages=593-598&rft.issn=0376-2491&rft_id=info:doi/10.3760/cma.j.issn.0376-2491.2020.08.006&rft_dat=%3Cproquest_pubme%3E2377346804%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2377346804&rft_id=info:pmid/32164113&rfr_iscdi=true |